Aligos Therapeutics, Inc. (NASDAQ:ALGS) Short Interest Up 30.7% in January

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 597,300 shares, a growth of 30.7% from the December 31st total of 457,100 shares. Currently, 22.4% of the shares of the company are sold short. Based on an average trading volume of 421,900 shares, the short-interest ratio is currently 1.4 days.

Aligos Therapeutics Trading Down 0.8 %

ALGS opened at $23.74 on Friday. Aligos Therapeutics has a 12-month low of $6.76 and a 12-month high of $46.80. The firm has a 50 day moving average of $32.59 and a two-hundred day moving average of $19.07. The firm has a market capitalization of $85.18 million, a PE ratio of -1.78 and a beta of 2.50.

Aligos Therapeutics (NASDAQ:ALGS) last issued its earnings results on Wednesday, November 6th. The company reported ($3.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.15) by ($0.92). Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. The business had revenue of $1.27 million for the quarter, compared to analysts’ expectations of $1.00 million. During the same period last year, the business earned ($10.25) EPS. As a group, analysts predict that Aligos Therapeutics will post -10.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Aligos Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. AlphaMark Advisors LLC raised its position in Aligos Therapeutics by 1,000.0% during the fourth quarter. AlphaMark Advisors LLC now owns 1,100 shares of the company’s stock valued at $44,000 after acquiring an additional 1,000 shares in the last quarter. Golden State Wealth Management LLC acquired a new stake in shares of Aligos Therapeutics during the 4th quarter worth approximately $107,000. Finally, Drive Wealth Management LLC purchased a new position in shares of Aligos Therapeutics during the 4th quarter valued at approximately $916,000. Institutional investors and hedge funds own 60.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Aligos Therapeutics in a research note on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).